Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Sequent Scientific Limited, was an unlisted public company incorporated on 16 August, 2002. It is classified as a public limited company and is located in , Maharashtra. It's authorized share capital was INR 5.00 cr and the total paid-up capital was INR 4.35 cr.
The current status of Sequent Scientific Limited is - Amalgamated.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2024 numbers.
9.29%
7.69%
-68.97%
2.15%
6.23%
5.07%
5.57
-0.31
-8.37
-8.01
-0.76
0.01
No Reports Available
Tofler currently has no financial reports
for this company due to a lack of available
information. This may be because the company
is dormant or closed (see company status)
or because it was formed only recently
(check the incorporation date) and financial data
is not yet available.
You can view basic information by scrolling through the page.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(1)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Arun Kumar Pillai | 00084845 | 22 years |
| Director | K R Ravishankar | 00084908 | 17 years |
| Director | Pallipuram Mathai Thampi | 00114522 | 17 years |
| Director | Deepak Calian Vaidya | 00337276 | 17 years |
| Director | Sharma Natraj Kannan | 00408118 | 19 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| SKANRAY HEALTHCARE PRIVATE LIMITED |
Amalgamated
|
7.1 Cr | 1 | Karnataka |
| STRIDES PHARMA SCIENCE LIMITED |
Active
|
92.0 Cr | 1 | Maharashtra |
| FRAXIS LIFE SCIENCES LIMITED |
Amalgamated
|
2.0 Cr | 2 | Maharashtra |
| ARCOLAB (INDIA) P.LTD. |
Amalgamated
|
1.0 L | 2 | Karnataka |
| ONESOURCE SPECIALTY PHARMA LIMITED |
Active
|
4.2 Cr | 1 | Karnataka |
| GRANDIX PHARMACEUTICALS LIMITED |
Amalgamated
|
46.4 L | 1 | Tamil Nadu |
| CHAYADEEP VENTURES LLP |
Active
|
1.0 L | 2 | Karnataka |
| AGNUS CAPITAL LLP |
Active
|
1.0 L | 2 | Karnataka |
| QUALICHEM REMEDIES LLP |
Active
|
1.0 L | 2 | Karnataka |
| SOLARA ACTIVE PHARMA SCIENCES LIMITED |
Active
|
40.2 Cr | 1 | Maharashtra |
| QUADGEN WIRELESS SOLUTIONS PRIVATE LIMITED |
Active
|
156.2 Cr | 1 | Karnataka |
| CARYL PHARMA PRIVATE LIMITED |
Amalgamated
|
43.5 L | 1 | Karnataka |
| TRIUMPH VENTURE HOLDINGS LLP |
Active
|
1.0 L | 1 | Karnataka |
| PIONEER BALLOON INDIA PRIVATE LIMITED |
Active
|
1.8 Cr | 1 | Karnataka |
| CHAITYADEEP INVESTMENTS PVT LTD |
Strike Off
|
1.0 L | 1 | Maharashtra |
| ORCHID RESEARCH LABORATORIES LIMITED |
Amalgamated
|
14.9 Cr | 1 | Tamil Nadu |
| CRISS FINANCIAL LIMITED |
Active
|
11.7 Cr | 1 | Telangana |
| SPIRACCA VENTURES LLP |
Active
|
6.0 L | 1 | Maharashtra |
| APOLLO MULTISPECIALITY HOSPITALS LIMITED |
Active
|
109.4 Cr | 1 | West Bengal |
| MARUDHAR HOTELS PVT LTD |
Active
|
43.8 L | 1 | Rajasthan |
| SPANDANA SPHOORTY FINANCIAL LIMITED |
Active
|
71.3 Cr | 1 | Telangana |
| API HOLDINGS LIMITED |
Active
|
686.2 Cr | 1 | Maharashtra |
| SUNTEC BUSINESS SOLUTIONS PRIVATE LIMITED |
Amalgamated
|
40.3 Cr | 1 | Tamil Nadu |
| GRANDIX LABORATORIES LIMITED |
Amalgamated
|
2.4 Cr | 1 | Tamil Nadu |
| QUANTUM REMEDIES PRIVATE LIMITED |
Amalgamated
|
1.0 L | 1 | Karnataka |
| RENEW AKSHAY URJA LIMITED |
Active
|
13.3 Cr | 1 | Delhi |
| SYMBIO GENERRICS INDIA PRIVATE LIMITED |
Active
|
3.0 Cr | 1 | Karnataka |
The incorporation date of SEQUENT SCIENTIFIC LIMITED is 16 August, 2002
The authorized share capital of SEQUENT SCIENTIFIC LIMITED is INR ₹ 5.0 Cr.
The paid-up capital of SEQUENT SCIENTIFIC LIMITED is INR ₹ 4.3 Cr.
The registered address of SEQUENT SCIENTIFIC LIMITED is 201 DEVARATASECTOR-17 VASHI NAVI MUMBAI Maharashtra - 400705
The CIN number of SEQUENT SCIENTIFIC LIMITED is U24110MH2002PLC136868.
Expand
Delete
Collapse
See
details
It will take sometime. Please come back in 10
minutes
